Drug Pricing

Blog

PRI-Manhattan Institute Forum Addresses California’s Drug Pricing Challenge

Earlier this week, PRI joined with the Manhattan Institute to host a well-attended Sacramento panel discussion on California’s drug pricing challenge. Many thanks to my friend and former longtime Capitol reporter Marcey Brightwell, who did an outstanding job moderating the event. Drug pricing emerged as one of the hottest issues ...
California

California’s Drug Pricing Challenge

Watch a Sacramento panel discussion on California’s drug pricing challenge, co-hosted by PRI and the Manhattan Institute. Moderated by former longtime Capitol journalist Marcey Brightwell, panelists include Dr. Tom Coburn of the Manhattan Institute (and former U.S. Senator from Oklahoma), PRI’s Sally Pipes, and Brett Johnson of the California Life ...
California

Unmistakable Signs That California Lawmakers Have (Yet Again) Gone Too Far

A Mercury News headline earlier this year declared that “Amid ‘Resistance,’ activists try to push California Democratic Party to the left.” But looking back now that the bill signing period is complete, it’s clear that Sacramento Democrats don’t need to be pushed left. They’re headed that way just fine on ...
Blog

The Price Control Hammer Will Break the Health Care System

From California to Washington D.C. legislators continue to confirm Abraham Kaplan’s famous insight that if you, “give a small boy a hammer, he will find that everything he encounters needs pounding.” In the case of our legislators, that hammer is price controls; and, what needs pounding is the price of ...
Business & Economics

Price Controls Will Reduce Innovation and Health Outcomes

Abraham Kaplan famously noted that if you, “give a small boy a hammer, he will find that everything he encounters needs pounding.” Put differently, solving problems requires the right tool, not the convenient tool. Congress should remember this wisdom in its upcoming deliberations regarding the cost of prescription drugs. The ...
Business & Economics

Reforming the 340B Program Will Lower the Price of Prescription Drugs

The U.S. health care system needs systemic reforms that comprehensively address the problems of declining quality and rising costs. Alas, beneficial systemic reforms will not be implemented any time soon. There are still opportunities for Congress to implement tailored reforms that can help address these problems in the near term. ...
Blog

U.S. Pharmaceutical Spending Is Below Average?

For the 30 nations that comprise the Organization for Economic Cooperation and Development (OECD), which promotes policies to improve the well-being of people around the world, pharmaceutical spending comprised, on average, 16.9 percent of total health care spending as of 2015. The OECD defines pharmaceutical spending as the expenditures on ...
Business & Economics

New Study Finds High Prescription Drug Costs Are Not Driving Up U.S. Healthcare Costs

It’s easy for politicians and consumers to rage about the high price of prescription drugs, but Wayne Winegarden, Pacific Research Institute’s senior fellow in business and economics, said those prices are not to blame for the high cost of healthcare in the United States. Recently, U.S. Bernie Sanders has been ...
Business & Economics

New PRI Study Finds That High Prescription Drug Costs Are Not Driving Up U.S. Health Care Costs

A more realistic evaluation of U.S. prescription drug prices shows that high drug prices are not actually driving up health care costs overall, and reflect the higher U.S. health care costs compared to the rest of the world, according to a new report released today by the Pacific Research Institute. ...
Business & Economics

Reform Pharmacy Benefit Managers (Pbms) To Improve Pharmaceutical Affordability

Imagine if you never had to directly pay for your morning cup of coffee again. Instead, a coffee insurer guaranteed that, for a small co-pay, you could enjoy a cup of coffee every morning. Sounds good? The catch, and there is always a catch, is the caveat “directly pay.” In ...
Blog

PRI-Manhattan Institute Forum Addresses California’s Drug Pricing Challenge

Earlier this week, PRI joined with the Manhattan Institute to host a well-attended Sacramento panel discussion on California’s drug pricing challenge. Many thanks to my friend and former longtime Capitol reporter Marcey Brightwell, who did an outstanding job moderating the event. Drug pricing emerged as one of the hottest issues ...
California

California’s Drug Pricing Challenge

Watch a Sacramento panel discussion on California’s drug pricing challenge, co-hosted by PRI and the Manhattan Institute. Moderated by former longtime Capitol journalist Marcey Brightwell, panelists include Dr. Tom Coburn of the Manhattan Institute (and former U.S. Senator from Oklahoma), PRI’s Sally Pipes, and Brett Johnson of the California Life ...
California

Unmistakable Signs That California Lawmakers Have (Yet Again) Gone Too Far

A Mercury News headline earlier this year declared that “Amid ‘Resistance,’ activists try to push California Democratic Party to the left.” But looking back now that the bill signing period is complete, it’s clear that Sacramento Democrats don’t need to be pushed left. They’re headed that way just fine on ...
Blog

The Price Control Hammer Will Break the Health Care System

From California to Washington D.C. legislators continue to confirm Abraham Kaplan’s famous insight that if you, “give a small boy a hammer, he will find that everything he encounters needs pounding.” In the case of our legislators, that hammer is price controls; and, what needs pounding is the price of ...
Business & Economics

Price Controls Will Reduce Innovation and Health Outcomes

Abraham Kaplan famously noted that if you, “give a small boy a hammer, he will find that everything he encounters needs pounding.” Put differently, solving problems requires the right tool, not the convenient tool. Congress should remember this wisdom in its upcoming deliberations regarding the cost of prescription drugs. The ...
Business & Economics

Reforming the 340B Program Will Lower the Price of Prescription Drugs

The U.S. health care system needs systemic reforms that comprehensively address the problems of declining quality and rising costs. Alas, beneficial systemic reforms will not be implemented any time soon. There are still opportunities for Congress to implement tailored reforms that can help address these problems in the near term. ...
Blog

U.S. Pharmaceutical Spending Is Below Average?

For the 30 nations that comprise the Organization for Economic Cooperation and Development (OECD), which promotes policies to improve the well-being of people around the world, pharmaceutical spending comprised, on average, 16.9 percent of total health care spending as of 2015. The OECD defines pharmaceutical spending as the expenditures on ...
Business & Economics

New Study Finds High Prescription Drug Costs Are Not Driving Up U.S. Healthcare Costs

It’s easy for politicians and consumers to rage about the high price of prescription drugs, but Wayne Winegarden, Pacific Research Institute’s senior fellow in business and economics, said those prices are not to blame for the high cost of healthcare in the United States. Recently, U.S. Bernie Sanders has been ...
Business & Economics

New PRI Study Finds That High Prescription Drug Costs Are Not Driving Up U.S. Health Care Costs

A more realistic evaluation of U.S. prescription drug prices shows that high drug prices are not actually driving up health care costs overall, and reflect the higher U.S. health care costs compared to the rest of the world, according to a new report released today by the Pacific Research Institute. ...
Business & Economics

Reform Pharmacy Benefit Managers (Pbms) To Improve Pharmaceutical Affordability

Imagine if you never had to directly pay for your morning cup of coffee again. Instead, a coffee insurer guaranteed that, for a small co-pay, you could enjoy a cup of coffee every morning. Sounds good? The catch, and there is always a catch, is the caveat “directly pay.” In ...
Scroll to Top